【佳学基因检测】外科肿瘤学的五个十年进展：乳腺

品牌肿瘤基因检测688套餐解剖

与专家交流肿瘤基因检测全面性的标准与实施方案《肿瘤突变基因检测与个性化治疗方案的制定》《J Surg Oncol》在. 2022 Oct;126(5):852-859.发表了一篇题目为《外科肿瘤学的五个十年进展：乳腺》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Stephanie Downs-Canner, Hiram S Cody rd 等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

胸部,手术进展,外科肿瘤学

肿瘤靶向治疗基因检测临床应用结果

手术仍然是乳腺癌最有效的单一治疗方法，但与此同时，随着对肿瘤生物学的深入了解和多学科护理（包括乳腺成像、全身辅助治疗、放射治疗和基因组学）的进步，在强有力的 I 级数据的支持下，该治疗继续降级.我们已经从乳房切除术转向保乳术，从常规腋窝清扫到前哨淋巴结活检，再到完全选择性省略腋窝淋巴结分期。我们通过对保乳边缘宽度的共识、通过改进新辅助治疗以及证明对 IV 期疾病患者的前期手术没有益处，进一步降级。对于同侧乳腺肿瘤复发的患者，再保留手术和再照射是有希望的。细胞周期和免疫检查点抑制剂，当添加到传统的全身治疗中时，现在已经从 IV 期疾病转移到辅助和新辅助环境中的 III 期试验，有望进一步降低手术规模。最后，通过基因组分析，我们正在摆脱腋窝淋巴结状态作为预测的首要地位，进入一个允许预测治疗反应的新时代。手术进展；外科肿瘤学。

肿瘤发生与复发转移国际数据库描述：

Surgery remains the single most effective treatment for breast cancer but coincident with a deeper understanding of tumor biology and advances in multidisciplinary care (encompassing breast imaging, systemic adjuvant therapy, radiotherapy, and genomics) continues to de-escalate, supported by strong level I data. We have moved from mastectomy to breast conservation, and from routine axillary dissection to sentinel lymph node biopsy to selective omission of axillary node staging altogether. We have further de-escalated through consensus over margin width in breast conservation, through improvements in neoadjuvant therapy, and by demonstrating no benefit for upfront surgery in patients with stage IV disease. For patients with ipsilateral breast tumor recurrence, reconservation surgery and reirradiation are promising. Cell cycle and immune checkpoint inhibitors, when added to conventional systemic therapy, have now moved beyond stage IV disease to phase III trials in the adjuvant and neoadjuvant settings, promising even further de-escalation of surgery. Finally, with genomic profiling we are moving away from the primacy of axillary node status for prognostication and into a new era allowing prediction of response to therapy.Keywords: breast; surgical advances; surgical oncology.